Patent intelligence · US
US 8940753
Methods for treating pruritis
Methods for treating pruritis
Patent details — US 8940753
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 27, 2015
- Expiration
- Jan 22, 2035
- Applicant
- Trevi Therapeutics, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K31/485, A61K45/06, A61K9/0053
Quick answer
US 8940753 (Methods for treating pruritis) is held by Trevi Therapeutics, Inc.. Status: granted. Granted Jan 27, 2015. Expires Jan 22, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Trevi Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/485, A61K45/06, A61K9/0053, A61K9/2009, A61K9/2013
More from Trevi Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12274696
Methods of administering nalbuphine
granted -
US 11660296
Treatment of chronic cough, breathlessness and dyspnea
granted -
US 10238646
Methods for treating pruritus
granted -
US 9624233
Compounds for treating pruritic conditions
granted -
US 8987289
Methods for treating pruritus
granted -
US 8637538
Methods for treatment of pruritis
granted
Frequently asked questions
What is US patent 8940753?
US 8940753 (Methods for treating pruritis) is held by Trevi Therapeutics, Inc.. Status: granted. Granted Jan 27, 2015. Expires Jan 22, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8940753?
Trevi Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 8940753 expire?
Our index shows an expiration date of Jan 22, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.